Magnesium hydroxide

Identification

Name
Magnesium hydroxide
Accession Number
DB09104
Type
Small Molecule
Groups
Approved, Investigational
Description

Magnesium hydroxide is an inorganic compound with the chemical formula Mg(OH)2. It is naturally found as the mineral brucite. Magnesium hydroxide can be used an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke supressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as an antiperspirant underarm deodorant or for relief of canker sores (aphthous ulcers).

Structure
Thumb
Synonyms
  • Magnesium dihydroxide
  • Milk of magnesia
External IDs
E-528 / INS NO.528 / INS-528
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Careone Milk Of MagnesiaSuspension1200 mg/15mLOralAmerican Sales Company2012-08-05Not applicableUs
Careone Milk Of MagnesiaSuspension1200 mg/15mLOralAmerican Sales Company2012-08-26Not applicableUs
Careone Milk Of MagnesiaSuspension1200 mg/15mLOralAmerican Sales Company2012-07-27Not applicableUs
Dermagran II Ointment - 0.25%Ointment.25 %TopicalTrans Canaderm Inc.1996-01-011996-09-10Canada
Dermagran II Ointment 0.25%Ointment.25 %TopicalCanadian Medical Supply Inc.1993-12-311996-09-09Canada
Dermagran II Ointment-ont Top 0.25%Ointment0.25 %TopicalCanderm G.P.1998-05-072008-08-06Canada
Dg Health Milk Of MagnesiaSuspension1200 mg/15mLOralDolgencorp2014-05-07Not applicableUs
Equaline Milk Of MagnesiaSuspension1200 mg/15mLOralSupervalu2004-10-14Not applicableUs
Equaline milk of magnesiaSuspension1200 mg/15mLOralSupervalu2004-10-14Not applicableUs
Equaline Milk Of MagnesiaSuspension1200 mg/15mLOralSupervalu2005-11-14Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Controller CompleteMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-052017-11-29Us
Acid Controller CompleteMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-052017-11-29Us
Acid Controller CompleteMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralSafeway2008-08-062017-12-22Us
Acid Controller Complete dual actionMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralWalgreen2008-07-30Not applicableUs
Acid Controller Complete dual actionMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralWalgreen2008-07-302018-03-29Us
Acid Reducer CompleteMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-06Not applicableUs
Acid Reducer CompleteMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Acid Reducer CompleteMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-12Not applicableUs
Acid Reducer CompleteMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralRite Aid2009-05-152018-04-01Us
Acid Reducer CompleteMagnesium hydroxide (165 mg/1) + Calcium Carbonate (800 mg/1) + Famotidine (10 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Categories
UNII
NBZ3QY004S
CAS number
1309-42-8
Weight
Average: 58.32
Monoisotopic: 57.990521206
Chemical Formula
H2MgO2
InChI Key
VTHJTEIRLNZDEV-UHFFFAOYSA-L
InChI
InChI=1S/Mg.2H2O/h;2*1H2/q+2;;/p-2
IUPAC Name
magnesium(2+) dihydroxide
SMILES
[OH-].[OH-].[Mg++]

Pharmacology

Indication

Magnesium hydroxide can be used as an antacid or a laxative depending on the administered dose.

As an antacid, it is used for the temporary relief of heartburn, upset stomach, sour stomach or acid indigestion.

As a laxative, it is used for the relief of occasional constipation by promoting bowel movements for 30 minutes and up to 6 hours.

Associated Conditions
Pharmacodynamics

As an antacid, magnesium hydroxide suspension neutralizes gastric acid by reacting with hydrochloric acid in the stomach to form magnesium chloride and water. It is practically insoluble in water and does not have any effect until it reacts with the hydrochloric acid in the stomach. There, it decreases the direct acid irritant effect and increases the pH in the stomach leading to inactivation of pepsin. Magnesium hydroxide enhances the integrity of the mucosal barrier of the stomach as well as improving the tone of both the gastric and esophageal sphincters.

As a laxative, the magnesium hydroxide works by increasing the osmotic effect in the intestinal tract and drawing water in. This creates distension of the colon which results in an increase in peristaltic movement and bowel evacuation.

Mechanism of action

The suspension of magnesium hydroxide is ingested and enters the stomach. According to the amount ingested, the magnesium hydroxide will either act as an antacid or a laxative.

Through the ingestion of 0.5-1.5 grams (in adults) the magnesium hydroxide will act by simple acid neutralization in the stomach. The hydroxide ions from the magnesium hydroxide suspension will combine with the acidic H+ ions of the hydrochloric acid made by the stomachs parietal cells. This neutralization reaction will result in the formation of magnesium chloride and water.

Through the ingestion of 2-5 grams (in adults) the magnesium hydroxide acts as a laxative in the colon. The majority of the suspension is not absorbed in the intestinal tract and will create an osmotic effect to draw water into the gut from surrounding tissues. With this increase of water in the intestines, the feces will soften and the intraluminal volume of the feces will increase. These effects still stimulate intestinal motility and induce the urge to defecate. Magnesium hydroxide will also release cholecystokinin (CKK) in the intestines which will accumulate water and electrolytes in the lumen and furthermore increase intestinal motility.

Absorption

About 15%-50% of magnesium hydroxide is absorbed very slowly through the small intestine.

Volume of distribution

The peak action and distribution of magnesium hydroxide are variable.

Protein binding

Magnesium hydroxide does not have any protein binding properties.

Metabolism

Unless a patient is deficient in magnesium, very little is absorbed by the intestine. Overall, about 15%-50% of the magnesium hydroxide suspension is absorbed systemically. However, it does not undergo any metabolism as it is rapidly excreted in the urine.

Route of elimination

After oral administration, up to 50% of the magnesium hydroxide suspension may be absorbed as magnesium ions through the small intestines and then rapidly excreted in the urine through the kidneys. The unabsorbed drug is mainly excreted in the feces and saliva.

Half life

N/A

Clearance

Magnesium hydroxide is mainly excreted in the urine by the kidneys. Since the kidneys play a major role in its clearance, individuals with renal failure are at risk of hypermagnesemia with long term consumption as the appropriate amounts of magnesium may not be excreted.

Toxicity

LD50=8500 mg/kg (rat, oral)

Common side effects include drowsiness or flushing (warmth, redness or tingly feeling).

Daily use of magnesium hydroxide can result in fluid and electrolyte disturbances.

Excessive use of the laxative effects of magnesium hydroxide may result in abdominal cramping, nausea and/or diarrhea.

In overdose, symptoms of gastrointestinal irritation and/or watery diarrhea may occur.

Magnesium hydroxide poisoning can result in hypermagnesemia which includes symptoms of: nausea, vomiting, flushing, thirst, hypotension, drowsiness, confusion, loss of tendon reflexes, muscle weakness, respiratory depression, cardiac arrhythmias, coma and cardiac arrest.

Not to be used in individuals with any form of kidney disease or renal failure, a magnesium restricted diet or with any sudden changes in bowel movement lasting over two weeks. Also not to be used in those individuals with abdominal pain, nausea, vomiting, symptoms of appendicitis or myocardial damage, heart block, fecal impaction, rectal fissures, intestinal obstruction or perforation or renal disease. Not to be used in women who are about to deliver as magnesium crosses the placenta and is excreted in small amounts in breast milk.

Using magnesium hydroxide with aluminum hydroxide can decrease the absorption rate of these drugs.

Magnesium hydroxide can react with digoxin, dicoumerol and cimetidine.

Use of ibuprofen with magnesium hydroxide can increase the absorption of the ibuprofen.

Use of magnesium hydroxide with penicallamine, bisphosphates, ketoconazole, quinolones or tetracycline can decrease the absorption of these drugs.

Enteric-coated tablets can be prematurely released when taken with magnesium hydroxide.

It is important to routinely monitor levels of serum magnesium and potassium in patients using magnesium hydroxide. Serum magnesium levels are necessary to determine how much magnesium is being absorbed and how much is being excreted by the kidneys. Excessive diarrhea can occur from use of magnesium hydroxide and thus it is important to also monitor serum potassium levels to ensure hypokalemia does not occur.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with (2-benzhydryloxyethyl)diethyl-methylammonium iodide.Experimental
2,5-Dimethoxy-4-ethylamphetamineMagnesium hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineMagnesium hydroxide may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3-Aza-2,3-Dihydrogeranyl DiphosphateThe serum concentration of 3-Aza-2,3-Dihydrogeranyl Diphosphate can be decreased when it is combined with Magnesium hydroxide.Experimental
3,4-MethylenedioxyamphetamineMagnesium hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineMagnesium hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Magnesium hydroxide.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Magnesium hydroxide.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Magnesium hydroxide.Experimental
AcepromazineMagnesium hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineMagnesium hydroxide can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetaminophenMagnesium hydroxide can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium hydroxide.Approved, Vet Approved
AcetophenazineMagnesium hydroxide can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Magnesium hydroxide.Experimental
AclidiniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aclidinium.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Magnesium hydroxide.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Magnesium hydroxide.Investigational
AgmatineThe risk or severity of hypotension and neuromuscular blockade can be increased when Agmatine is combined with Magnesium hydroxide.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Magnesium hydroxide.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Alaproclate.Experimental
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium hydroxide.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium hydroxide.Experimental
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium hydroxide.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium hydroxide.Approved
AlfacalcidolThe serum concentration of Magnesium hydroxide can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Magnesium hydroxide.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Magnesium hydroxide.Approved, Illicit
AlimemazineMagnesium hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Magnesium hydroxide.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Magnesium hydroxide.Investigational
AllopurinolMagnesium hydroxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlmasilateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Almasilate.Approved, Experimental
AloglutamolThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aloglutamol.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Magnesium hydroxide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Magnesium hydroxide.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Magnesium hydroxide.Approved, Illicit, Investigational
Aluminium acetoacetateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aluminium acetoacetate.Experimental
Aluminium glycinateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aluminium glycinate.Experimental
Aluminum hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium hydroxide.Approved
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Magnesium hydroxide.Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Magnesium hydroxide.Illicit, Withdrawn
AmiodaroneThe risk or severity of hypotension and neuromuscular blockade can be increased when Amiodarone is combined with Magnesium hydroxide.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Magnesium hydroxide.Approved, Investigational
AmitriptylineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Magnesium hydroxide.Approved, Investigational
AmlodipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Amlodipine is combined with Magnesium hydroxide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Magnesium hydroxide.Approved, Illicit
AmoxapineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Magnesium hydroxide.Experimental
AmphetamineMagnesium hydroxide may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Magnesium hydroxide.Experimental
Anisotropine MethylbromideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Anisotropine Methylbromide.Approved
ApramycinThe risk or severity of adverse effects can be increased when Apramycin is combined with Magnesium hydroxide.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Magnesium hydroxide.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Magnesium hydroxide.Experimental
AranidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Aranidipine is combined with Magnesium hydroxide.Approved, Investigational
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Magnesium hydroxide.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Arbekacin is combined with Magnesium hydroxide.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Aripiprazole lauroxil is combined with Magnesium hydroxide.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Magnesium hydroxide.Approved
AtazanavirMagnesium hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Magnesium hydroxide.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium hydroxide.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium hydroxide.Approved
AtropineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Atropine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Magnesium hydroxide.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Magnesium hydroxide.Investigational
AzelastineMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Azelnidipine is combined with Magnesium hydroxide.Approved, Investigational
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Magnesium hydroxide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Magnesium hydroxide.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Magnesium hydroxide.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Magnesium hydroxide.Illicit
BarnidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Barnidipine is combined with Magnesium hydroxide.Approved
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Magnesium hydroxide.Experimental
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium hydroxide.Approved, Investigational
BekanamycinThe risk or severity of adverse effects can be increased when Bekanamycin is combined with Magnesium hydroxide.Experimental
BenactyzineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Benactyzine.Withdrawn
BenazeprilMagnesium hydroxide can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BenazeprilatMagnesium hydroxide can cause a decrease in the absorption of Benazeprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BencyclaneThe risk or severity of hypotension and neuromuscular blockade can be increased when Bencyclane is combined with Magnesium hydroxide.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Magnesium hydroxide.Approved
BenidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Benidipine is combined with Magnesium hydroxide.Approved, Investigational
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Magnesium hydroxide.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Magnesium hydroxide.Approved, Investigational
BenzatropineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Benzatropine.Approved
BenziloneThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Benzilone.Experimental
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Magnesium hydroxide.Approved
BenzphetamineMagnesium hydroxide may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BenzquinamideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Benzquinamide.Withdrawn
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Magnesium hydroxide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Magnesium hydroxide.Approved
BepridilThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium hydroxide.Approved, Withdrawn
BesifloxacinMagnesium hydroxide can cause a decrease in the absorption of Besifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
BevoniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Magnesium hydroxide.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Magnesium hydroxide.Investigational
BioallethrinThe risk or severity of hypotension and neuromuscular blockade can be increased when Bioallethrin is combined with Magnesium hydroxide.Approved, Experimental
BiperidenThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Biperiden.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium hydroxide.Approved
BL-1020Magnesium hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Blonanserin is combined with Magnesium hydroxide.Approved, Investigational
BornaprineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Bornaprine.Experimental
BosutinibMagnesium hydroxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Magnesium hydroxide.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved
BrinzolamideThe risk or severity of adverse effects can be increased when Brinzolamide is combined with Magnesium hydroxide.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Magnesium hydroxide.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Magnesium hydroxide.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Magnesium hydroxide.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Magnesium hydroxide.Experimental
BromotheophyllineThe risk or severity of adverse effects can be increased when Bromotheophylline is combined with Magnesium hydroxide.Approved
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Magnesium hydroxide.Approved, Investigational
BrompheniramineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
BuclizineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Buclizine.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium hydroxide.Approved
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Magnesium hydroxide.Experimental, Illicit
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Magnesium hydroxide.Approved
BuprenorphineMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Magnesium hydroxide.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Magnesium hydroxide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Magnesium hydroxide.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Magnesium hydroxide.Approved, Illicit
ButaperazineMagnesium hydroxide can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Magnesium hydroxide.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Magnesium hydroxide.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Magnesium hydroxide.Approved
ButylscopolamineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Butylscopolamine.Approved, Investigational, Vet Approved
CalcitriolThe serum concentration of Magnesium hydroxide can be increased when it is combined with Calcitriol.Approved, Nutraceutical
Calcium CarbonateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium PhosphateThe serum concentration of Calcium Phosphate can be decreased when it is combined with Magnesium hydroxide.Approved
Calcium phosphate dihydrateThe serum concentration of Calcium phosphate dihydrate can be decreased when it is combined with Magnesium hydroxide.Approved
Calcium silicateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Calcium silicate.Experimental
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Magnesium hydroxide.Approved, Illicit
CamylofinThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Camylofin.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Magnesium hydroxide.Approved
CannabidivarinThe risk or severity of adverse effects can be increased when Cannabidivarin is combined with Magnesium hydroxide.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Canrenoic acid is combined with Magnesium hydroxide.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Canrenone is combined with Magnesium hydroxide.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Magnesium hydroxide.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Magnesium hydroxide.Approved, Investigational
CaptoprilMagnesium hydroxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Magnesium hydroxide.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Magnesium hydroxide.Approved
CarboxyamidotriazoleThe risk or severity of hypotension and neuromuscular blockade can be increased when Carboxyamidotriazole is combined with Magnesium hydroxide.Investigational
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Magnesium hydroxide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Magnesium hydroxide.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Magnesium hydroxide.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Magnesium hydroxide.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Magnesium hydroxide.Approved
CaroverineThe risk or severity of hypotension and neuromuscular blockade can be increased when Caroverine is combined with Magnesium hydroxide.Experimental
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Magnesium hydroxide.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Magnesium hydroxide.Illicit
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium hydroxide.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium hydroxide.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Magnesium hydroxide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Magnesium hydroxide.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Magnesium hydroxide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
ChloroquineMagnesium hydroxide can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Magnesium hydroxide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Magnesium hydroxide.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenesin is combined with Magnesium hydroxide.Approved, Vet Approved, Withdrawn
ChlorphenoxamineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Chlorphenoxamine.Withdrawn
ChlorphentermineMagnesium hydroxide may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineMagnesium hydroxide can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineMagnesium hydroxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Magnesium hydroxide.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Magnesium hydroxide.Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium hydroxide.Approved, Investigational
CicletanineThe risk or severity of adverse effects can be increased when Cicletanine is combined with Magnesium hydroxide.Investigational
CilazaprilMagnesium hydroxide can cause a decrease in the absorption of Cilazapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CilnidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Cilnidipine is combined with Magnesium hydroxide.Approved, Investigational
CinnarizineThe risk or severity of hypotension and neuromuscular blockade can be increased when Cinnarizine is combined with Magnesium hydroxide.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Magnesium hydroxide.Approved
CinoxacinMagnesium hydroxide can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinMagnesium hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Magnesium hydroxide.Approved
CitalopramThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Magnesium hydroxide.Approved, Investigational
ClevidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Clevidipine is combined with Magnesium hydroxide.Approved, Investigational
ClidiniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Magnesium hydroxide.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Magnesium hydroxide.Approved, Illicit
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium hydroxide.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Magnesium hydroxide.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium hydroxide.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
ClofenamideThe risk or severity of adverse effects can be increased when Clofenamide is combined with Magnesium hydroxide.Experimental
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Magnesium hydroxide.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
ClomocyclineMagnesium hydroxide can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Magnesium hydroxide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Magnesium hydroxide.Approved
ClopamideThe risk or severity of adverse effects can be increased when Clopamide is combined with Magnesium hydroxide.Experimental
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Magnesium hydroxide.Experimental
CloprednolThe bioavailability of Cloprednol can be decreased when combined with Magnesium hydroxide.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Magnesium hydroxide.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Clorexolone is combined with Magnesium hydroxide.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Magnesium hydroxide.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Magnesium hydroxide.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Magnesium hydroxide.Approved, Investigational
ClozapineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Clozapine.Approved
CocaineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Magnesium hydroxide.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Colistimethate is combined with Magnesium hydroxide.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Magnesium hydroxide.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Magnesium hydroxide.Approved, Investigational
CorticotropinThe bioavailability of Corticotropin can be decreased when combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium hydroxide.Approved, Investigational
CortivazolThe bioavailability of Cortivazol can be decreased when combined with Magnesium hydroxide.Investigational
CyamemazineMagnesium hydroxide can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CyclandelateThe risk or severity of hypotension and neuromuscular blockade can be increased when Cyclandelate is combined with Magnesium hydroxide.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Magnesium hydroxide.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Magnesium hydroxide.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Magnesium hydroxide.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Cyclopentamine.Withdrawn
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Magnesium hydroxide.Experimental
CyclopentolateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Cyclopentolate.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Magnesium hydroxide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Cyclothiazide is combined with Magnesium hydroxide.Approved
CycrimineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Cycrimine.Approved
CyproheptadineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Cyproheptadine.Approved
CysteamineThe bioavailability of Cysteamine can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Dabigatran etexilateMagnesium hydroxide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DabrafenibMagnesium hydroxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Magnesium hydroxide.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium hydroxide.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Magnesium hydroxide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Dapoxetine.Investigational
DarifenacinThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Darodipine is combined with Magnesium hydroxide.Experimental
DasatinibMagnesium hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Magnesium hydroxide.Experimental
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium hydroxide.Approved
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium hydroxide.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Magnesium hydroxide.Approved, Investigational
DelaprilMagnesium hydroxide can cause a decrease in the absorption of Delapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
DelavirdineMagnesium hydroxide can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Magnesium hydroxide.Approved, Illicit, Investigational
DemeclocyclineMagnesium hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Magnesium hydroxide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Magnesium hydroxide.Approved
DesipramineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Magnesium hydroxide.Approved, Investigational
DesonideThe bioavailability of Desonide can be decreased when combined with Magnesium hydroxide.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium hydroxide.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Magnesium hydroxide.Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magnesium hydroxide.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium hydroxide.Approved
DexetimideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Dexetimide.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Magnesium hydroxide.Approved, Vet Approved
DexmethylphenidateMagnesium hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DexniguldipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Dexniguldipine is combined with Magnesium hydroxide.Experimental
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Magnesium hydroxide.Investigational
DextroamphetamineMagnesium hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Magnesium hydroxide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Magnesium hydroxide.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe risk or severity of hypotension and neuromuscular blockade can be increased when Dexverapamil is combined with Magnesium hydroxide.Experimental
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Magnesium hydroxide.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Magnesium hydroxide.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Dibekacin is combined with Magnesium hydroxide.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Magnesium hydroxide.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Magnesium hydroxide.Approved, Illicit
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Magnesium hydroxide.Approved, Investigational
DicyclomineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Dicyclomine.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Magnesium hydroxide.Experimental
DiethylpropionMagnesium hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DifemerineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Difemerine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Magnesium hydroxide.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium hydroxide.Approved
DifloxacinMagnesium hydroxide can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium hydroxide.Approved
DihexyverineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Dihexyverine.Experimental
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Magnesium hydroxide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Magnesium hydroxide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Magnesium hydroxide.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Magnesium hydroxide.Investigational, Vet Approved
DiltiazemThe risk or severity of hypotension and neuromuscular blockade can be increased when Diltiazem is combined with Magnesium hydroxide.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Magnesium hydroxide.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Magnesium hydroxide.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Magnesium hydroxide.Experimental, Illicit
DimetindeneThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Dimetindene.Approved, Investigational
DiphemanilThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Diphemanil.Experimental
Diphemanil MethylsulfateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Diphemanil Methylsulfate.Approved, Vet Approved, Withdrawn
DiphenhydramineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Diphenhydramine.Approved, Investigational
DiphenidolThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Diphenidol.Approved, Investigational, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Magnesium hydroxide.Approved, Illicit
Dipotassium phosphateThe serum concentration of Dipotassium phosphate can be decreased when it is combined with Magnesium hydroxide.Approved
DisopyramideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Disopyramide.Approved
DixyrazineMagnesium hydroxide can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium hydroxide.Approved
Domoic AcidThe risk or severity of adverse effects can be increased when Domoic Acid is combined with Magnesium hydroxide.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Magnesium hydroxide.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Magnesium hydroxide.Vet Approved
DorzolamideThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Magnesium hydroxide.Approved
DosulepinThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Dosulepin.Approved
DotarizineThe risk or severity of hypotension and neuromuscular blockade can be increased when Dotarizine is combined with Magnesium hydroxide.Investigational
DoxacuriumThe therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium hydroxide.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Magnesium hydroxide.Experimental
DoxepinThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Doxepin.Approved, Investigational
DoxycyclineMagnesium hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Magnesium hydroxide.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium hydroxide.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Magnesium hydroxide.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Magnesium hydroxide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Magnesium hydroxide.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Magnesium hydroxide.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Magnesium hydroxide.Approved, Investigational
EfonidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Efonidipine is combined with Magnesium hydroxide.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Magnesium hydroxide.Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium hydroxide.Approved
EluxadolineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Eluxadoline.Approved, Investigational
ElvitegravirMagnesium hydroxide can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EmeproniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Emepronium.Experimental
EmopamilThe risk or severity of hypotension and neuromuscular blockade can be increased when Emopamil is combined with Magnesium hydroxide.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Magnesium hydroxide.Approved
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Magnesium hydroxide.Experimental
EnalaprilMagnesium hydroxide can cause a decrease in the absorption of Enalapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
EnalaprilatMagnesium hydroxide can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
EnoxacinMagnesium hydroxide can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Magnesium hydroxide.Approved, Investigational
EperisoneThe risk or severity of hypotension and neuromuscular blockade can be increased when Eperisone is combined with Magnesium hydroxide.Approved, Investigational
EpitizideThe risk or severity of adverse effects can be increased when Epitizide is combined with Magnesium hydroxide.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Magnesium hydroxide.Approved
ErlotinibMagnesium hydroxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Magnesium hydroxide.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Magnesium hydroxide.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Esreboxetine is combined with Magnesium hydroxide.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Magnesium hydroxide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Magnesium hydroxide.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Magnesium hydroxide.Approved, Investigational
EtanautineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Etanautine.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Magnesium hydroxide.Experimental
EthanolMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Magnesium hydroxide.Approved, Illicit, Withdrawn
EthopropazineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ethopropazine.Approved
EthosuximideThe risk or severity of hypotension and neuromuscular blockade can be increased when Ethosuximide is combined with Magnesium hydroxide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Magnesium hydroxide.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Magnesium hydroxide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Magnesium hydroxide.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Magnesium hydroxide.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Magnesium hydroxide.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Magnesium hydroxide.Approved, Illicit
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium hydroxide.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Magnesium hydroxide.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Magnesium hydroxide.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Magnesium hydroxide.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium hydroxide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Magnesium hydroxide.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Magnesium hydroxide.Illicit, Vet Approved
EtybenzatropineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Etybenzatropine.Experimental
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Magnesium hydroxide.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Magnesium hydroxide.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Magnesium hydroxide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Magnesium hydroxide.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Magnesium hydroxide.Approved
FelodipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Felodipine is combined with Magnesium hydroxide.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Magnesium hydroxide.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension and neuromuscular blockade can be increased when Fendiline is combined with Magnesium hydroxide.Withdrawn
FenpiveriniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Fenpiverinium.Experimental
FenquizoneThe risk or severity of adverse effects can be increased when Fenquizone is combined with Magnesium hydroxide.Experimental
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Magnesium hydroxide.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Magnesium hydroxide.Experimental
Ferric ammonium citrateMagnesium hydroxide can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseMagnesium hydroxide can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationMagnesium hydroxide can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideMagnesium hydroxide can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideMagnesium hydroxide can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateThe serum concentration of Ferric pyrophosphate can be decreased when it is combined with Magnesium hydroxide.Experimental
Ferric pyrophosphate citrateThe serum concentration of Ferric pyrophosphate citrate can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Ferric subsulfateMagnesium hydroxide can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateMagnesium hydroxide can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateMagnesium hydroxide can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideMagnesium hydroxide can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateMagnesium hydroxide can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateMagnesium hydroxide can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateMagnesium hydroxide can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateMagnesium hydroxide can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesMagnesium hydroxide can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilMagnesium hydroxide can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolMagnesium hydroxide can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FesoterodineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Fesoterodine.Approved
FexofenadineMagnesium hydroxide can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Fish oilThe risk or severity of hypotension and neuromuscular blockade can be increased when Fish oil is combined with Magnesium hydroxide.Approved, Nutraceutical
FlavoxateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Flavoxate.Approved
FleroxacinMagnesium hydroxide can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Magnesium hydroxide.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Magnesium hydroxide.Experimental
FlucloroloneThe bioavailability of Fluclorolone can be decreased when combined with Magnesium hydroxide.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Magnesium hydroxide.Approved, Illicit
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
FlumequineMagnesium hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
FlunarizineThe risk or severity of hypotension and neuromuscular blockade can be increased when Flunarizine is combined with Magnesium hydroxide.Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Magnesium hydroxide.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Magnesium hydroxide.Approved, Illicit
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium hydroxide.Approved, Investigational
FluocortinThe bioavailability of Fluocortin can be decreased when combined with Magnesium hydroxide.Experimental
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium hydroxide.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe bioavailability of Fluperolone can be decreased when combined with Magnesium hydroxide.Experimental
FluphenazineMagnesium hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium hydroxide.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magnesium hydroxide.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium hydroxide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Magnesium hydroxide.Approved, Illicit, Investigational
FluspirileneThe risk or severity of hypotension and neuromuscular blockade can be increased when Fluspirilene is combined with Magnesium hydroxide.Approved, Investigational
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Magnesium hydroxide.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium hydroxide.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Magnesium hydroxide.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Fluvoxamine.Approved, Investigational
FormocortalThe bioavailability of Formocortal can be decreased when combined with Magnesium hydroxide.Experimental
FosinoprilMagnesium hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FosinoprilatMagnesium hydroxide can cause a decrease in the absorption of Fosinoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Magnesium hydroxide.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Magnesium hydroxide.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Framycetin is combined with Magnesium hydroxide.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Magnesium hydroxide.Approved, Vet Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Magnesium hydroxide.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Magnesium hydroxide.Investigational
GallamineThe therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium hydroxide.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be increased when used in combination with Magnesium hydroxide.Approved
GallopamilThe risk or severity of hypotension and neuromuscular blockade can be increased when Gallopamil is combined with Magnesium hydroxide.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Magnesium hydroxide.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Magnesium hydroxide.Investigational
GarenoxacinMagnesium hydroxide can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinMagnesium hydroxide can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Magnesium hydroxide.Experimental
GefitinibMagnesium hydroxide can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinMagnesium hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GeneticinThe risk or severity of adverse effects can be increased when Geneticin is combined with Magnesium hydroxide.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Gentamicin is combined with Magnesium hydroxide.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with GENTAMICIN C1A.Experimental
GepefrineMagnesium hydroxide may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Magnesium hydroxide.Investigational
Geranyl DiphosphateThe serum concentration of Geranyl Diphosphate can be decreased when it is combined with Magnesium hydroxide.Experimental
Geranylgeranyl diphosphateThe serum concentration of Geranylgeranyl diphosphate can be decreased when it is combined with Magnesium hydroxide.Experimental
GleptoferronMagnesium hydroxide can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Magnesium hydroxide.Approved, Illicit
GlycopyrroniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Glycopyrronium.Approved, Investigational, Vet Approved
GrepafloxacinMagnesium hydroxide can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Magnesium hydroxide.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Magnesium hydroxide.Approved, Illicit, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
HalometasoneThe bioavailability of Halometasone can be decreased when combined with Magnesium hydroxide.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Magnesium hydroxide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Magnesium hydroxide.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Magnesium hydroxide.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Magnesium hydroxide.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Magnesium hydroxide.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Magnesium hydroxide.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Magnesium hydroxide.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Magnesium hydroxide.Approved
HexocycliumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Hexocyclium.Approved
HomatropineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Homatropine.Approved
Homatropine MethylbromideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Homatropine Methylbromide.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Magnesium hydroxide.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Magnesium hydroxide.Approved, Vet Approved
HydrocodoneMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
Hydrocortisone aceponateThe bioavailability of Hydrocortisone aceponate can be decreased when combined with Magnesium hydroxide.Experimental, Vet Approved
Hydrocortisone acetateThe bioavailability of Hydrocortisone acetate can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
Hydrocortisone butyrateThe bioavailability of Hydrocortisone butyrate can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
Hydrocortisone probutateThe bioavailability of Hydrocortisone probutate can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
Hydrocortisone succinateThe bioavailability of Hydrocortisone succinate can be decreased when combined with Magnesium hydroxide.Approved
Hydrocortisone valerateThe bioavailability of Hydrocortisone valerate can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Magnesium hydroxide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Magnesium hydroxide.Approved, Illicit
HydrotalciteThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Hydrotalcite.Approved, Experimental, Investigational
HydroxyamphetamineMagnesium hydroxide may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Hygromycin B is combined with Magnesium hydroxide.Vet Approved
HyoscyamineMagnesium hydroxide can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Magnesium hydroxide.Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
IbopamineThe risk or severity of adverse effects can be increased when Ibopamine is combined with Magnesium hydroxide.Experimental
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Magnesium hydroxide.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Magnesium hydroxide.Investigational
ImidafenacinThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Imidafenacin.Approved, Investigational
ImidaprilMagnesium hydroxide can cause a decrease in the absorption of Imidapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
ImipramineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Imipramine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Magnesium hydroxide.Experimental
Incadronic acidThe serum concentration of Incadronic acid can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
IndalpineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Magnesium hydroxide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Magnesium hydroxide.Investigational
Iofetamine I-123Magnesium hydroxide may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IpratropiumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Ipratropium.Approved
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Magnesium hydroxide.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Magnesium hydroxide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Magnesium hydroxide.Withdrawn
IronMagnesium hydroxide can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMagnesium hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Magnesium hydroxide can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateMagnesium hydroxide can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsepamicinThe risk or severity of adverse effects can be increased when Isepamicin is combined with Magnesium hydroxide.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Magnesium hydroxide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Magnesium hydroxide.Approved, Vet Approved
IsopropamideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Isopropamide.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Isosorbide is combined with Magnesium hydroxide.Approved, Investigational
IsradipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Isradipine is combined with Magnesium hydroxide.Approved, Investigational
ItraconazoleMagnesium hydroxide can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium hydroxide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Magnesium hydroxide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Magnesium hydroxide.Approved, Investigational
KetoconazoleMagnesium hydroxide can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium hydroxide.Approved, Nutraceutical, Withdrawn
LacidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Lacidipine is combined with Magnesium hydroxide.Approved, Investigational
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Magnesium hydroxide.Approved
LamotrigineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Lamotrigine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Magnesium hydroxide.Investigational
LedipasvirMagnesium hydroxide can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LercanidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Lercanidipine is combined with Magnesium hydroxide.Approved, Investigational
LevetiracetamThe risk or severity of hypotension and neuromuscular blockade can be increased when Levetiracetam is combined with Magnesium hydroxide.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Magnesium hydroxide.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Magnesium hydroxide.Approved
LevofloxacinMagnesium hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Magnesium hydroxide.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Magnesium hydroxide.Approved
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium hydroxide.Approved
LidoflazineThe risk or severity of hypotension and neuromuscular blockade can be increased when Lidoflazine is combined with Magnesium hydroxide.Experimental
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Magnesium hydroxide.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Linezolid.Approved, Investigational
Lipoic AcidMagnesium hydroxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
LisdexamfetamineMagnesium hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LisinoprilMagnesium hydroxide can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Magnesium hydroxide.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Magnesium hydroxide.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Magnesium hydroxide.Experimental
LofexidineThe therapeutic efficacy of Magnesium hydroxide can be increased when used in combination with Lofexidine.Approved, Investigational
LomefloxacinMagnesium hydroxide can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LomerizineThe risk or severity of hypotension and neuromuscular blockade can be increased when Lomerizine is combined with Magnesium hydroxide.Experimental
LoperamideThe risk or severity of hypotension and neuromuscular blockade can be increased when Loperamide is combined with Magnesium hydroxide.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Magnesium hydroxide.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Magnesium hydroxide.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Magnesium hydroxide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Magnesium hydroxide.Approved
LortalamineThe risk or severity of adverse effects can be increased when Lortalamine is combined with Magnesium hydroxide.Experimental
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Magnesium hydroxide.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Magnesium hydroxide.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Lumateperone is combined with Magnesium hydroxide.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Magnesium hydroxide.Approved, Investigational
LymecyclineMagnesium hydroxide can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Magnesium hydroxide.Illicit, Investigational, Withdrawn
MagaldrateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Magaldrate.Approved, Withdrawn
Magnesium acetateThe risk or severity of adverse effects can be increased when Magnesium acetate is combined with Magnesium hydroxide.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Magnesium acetate tetrahydrate is combined with Magnesium hydroxide.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Magnesium Aluminum Silicate is combined with Magnesium hydroxide.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Magnesium hydroxide.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Magnesium hydroxide.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Magnesium cation is combined with Magnesium hydroxide.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Magnesium chloride is combined with Magnesium hydroxide.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Magnesium hydroxide.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Magnesium gluconate is combined with Magnesium hydroxide.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Magnesium glycinate is combined with Magnesium hydroxide.Approved
Magnesium orotateThe risk or severity of adverse effects can be increased when Magnesium orotate is combined with Magnesium hydroxide.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Magnesium hydroxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Magnesium phosphate is combined with Magnesium hydroxide.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when Magnesium silicate is combined with Magnesium hydroxide.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Magnesium stearate is combined with Magnesium hydroxide.Investigational
Magnesium sulfateThe therapeutic efficacy of Magnesium hydroxide can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Magnesium hydroxide.Approved
ManidipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Manidipine is combined with Magnesium hydroxide.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Magnesium hydroxide.Approved, Investigational
MaprotilineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Maprotiline.Approved, Investigational
MazaticolThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Mazaticol.Experimental
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Magnesium hydroxide.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Magnesium hydroxide.Withdrawn
MebeverineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Mebeverine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Magnesium hydroxide.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Magnesium hydroxide.Approved
MebutizideThe risk or severity of adverse effects can be increased when Mebutizide is combined with Magnesium hydroxide.Experimental
MecamylamineMagnesium hydroxide may decrease the excretion rate of Mecamylamine which could result in a higher serum level.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Magnesium hydroxide.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Magnesium hydroxide.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Magnesium hydroxide.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Magnesium hydroxide.Experimental
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium hydroxide.Approved
MefrusideThe risk or severity of adverse effects can be increased when Mefruside is combined with Magnesium hydroxide.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Magnesium hydroxide.Approved, Nutraceutical, Vet Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magnesium hydroxide.Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Magnesium hydroxide.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Magnesium hydroxide.Approved, Investigational
MemantineMagnesium hydroxide may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Investigational
MentholThe risk or severity of hypotension and neuromuscular blockade can be increased when Menthol is combined with Magnesium hydroxide.Approved
MepenzolateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Mepenzolate.Approved
MephedroneMagnesium hydroxide may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Magnesium hydroxide.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Magnesium hydroxide.Experimental
MephentermineMagnesium hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Magnesium hydroxide.Investigational, Withdrawn
MeprednisoneThe bioavailability of Meprednisone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Magnesium hydroxide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Magnesium hydroxide.Experimental
MersalylThe risk or severity of adverse effects can be increased when Mersalyl is combined with Magnesium hydroxide.Approved
MesalazineMagnesium hydroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MesoridazineMagnesium hydroxide can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Magnesium hydroxide.Approved
MethacyclineMagnesium hydroxide can cause a decrease in the absorption of Methacycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Magnesium hydroxide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Magnesium hydroxide.Approved, Illicit
MethamphetamineMagnesium hydroxide may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethanthelineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Methantheline.Approved, Investigational
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Magnesium hydroxide.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Magnesium hydroxide.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Magnesium hydroxide.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Magnesium hydroxide.Approved
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Magnesium hydroxide.Approved, Vet Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Magnesium hydroxide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Magnesium hydroxide.Approved
MethotrimeprazineMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
MethoxyphenamineMagnesium hydroxide may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
MethscopolamineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Methscopolamine.Approved
MethsuximideThe risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium hydroxide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Magnesium hydroxide.Approved
Methylene blueMagnesium hydroxide can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Magnesium hydroxide.Experimental
MethylphenidateMagnesium hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Magnesium hydroxide.Approved
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Methylscopolamine bromide.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Magnesium hydroxide.Approved, Illicit, Withdrawn
MeticraneThe risk or severity of adverse effects can be increased when Meticrane is combined with Magnesium hydroxide.Experimental
MetixeneThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Metixene.Approved
MetocurineThe therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium hydroxide.Approved
Metocurine IodideThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Magnesium hydroxide.Approved, Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Magnesium hydroxide.Approved
MetyrosineMagnesium hydroxide may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Magnesium hydroxide.Approved, Investigational
MibefradilThe risk or severity of hypotension and neuromuscular blockade can be increased when Mibefradil is combined with Magnesium hydroxide.Investigational, Withdrawn
MicronomicinThe risk or severity of adverse effects can be increased when Micronomicin is combined with Magnesium hydroxide.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Magnesium hydroxide.Approved, Illicit
MidomafetamineMagnesium hydroxide may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Magnesium hydroxide.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved, Investigational
MirtazapineMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MisoprostolThe serum concentration of Misoprostol can be decreased when it is combined with Magnesium hydroxide.Approved
MivacuriumThe therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium hydroxide.Approved
MMDAMagnesium hydroxide may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Magnesium hydroxide.Approved, Investigational
MoexiprilMagnesium hydroxide can cause a decrease in the absorption of Moexipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Magnesium hydroxide.Approved
MometasoneThe bioavailability of Mometasone can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
Mometasone furoateThe bioavailability of Mometasone furoate can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
Monopotassium phosphateThe serum concentration of Monopotassium phosphate can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Magnesium hydroxide.Experimental
MoricizineMagnesium hydroxide can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Magnesium hydroxide.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Magnesium hydroxide.Experimental
MoxifloxacinMagnesium hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Magnesium hydroxide.Experimental
MuzolimineThe risk or severity of adverse effects can be increased when Muzolimine is combined with Magnesium hydroxide.Experimental
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium hydroxide.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved, Investigational
NaftopidilThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium hydroxide.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Magnesium hydroxide.Approved
Nalidixic AcidMagnesium hydroxide can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaltrexoneThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NeamineThe risk or severity of adverse effects can be increased when Neamine is combined with Magnesium hydroxide.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Magnesium hydroxide.Investigational
NemonoxacinMagnesium hydroxide can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Magnesium hydroxide.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Magnesium hydroxide.Approved, Vet Approved
NeosaxitoxinThe therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium hydroxide.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Netilmicin is combined with Magnesium hydroxide.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Magnesium hydroxide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Magnesium hydroxide.Experimental
NicardipineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Nicardipine.Approved, Investigational
NicomorphineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Nicomorphine.Experimental
NicotineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Nicotine.Approved
NifedipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Nifedipine is combined with Magnesium hydroxide.Approved
NiguldipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Niguldipine is combined with Magnesium hydroxide.Experimental
NilotinibMagnesium hydroxide can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NiludipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Niludipine is combined with Magnesium hydroxide.Experimental
NilvadipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Nilvadipine is combined with Magnesium hydroxide.Approved, Investigational
NimesulideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nimesulide is combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Nimodipine is combined with Magnesium hydroxide.Approved, Investigational
NisoldipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium hydroxide.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Nisoxetine is combined with Magnesium hydroxide.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Magnesium hydroxide.Approved
NitrendipineThe risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium hydroxide.Approved, Investigational
NitroprussideMagnesium hydroxide can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Magnesium hydroxide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Magnesium hydroxide.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Magnesium hydroxide.Approved
NorfloxacinMagnesium hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Magnesium hydroxide.Approved, Illicit
NortriptylineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Nortriptyline.Approved
NylidrinThe risk or severity of hypotension and neuromuscular blockade can be increased when Nylidrin is combined with Magnesium hydroxide.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Magnesium hydroxide.Withdrawn
OfloxacinMagnesium hydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OlanzapineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium hydroxide.Approved
OmapatrilatMagnesium hydroxide can cause a decrease in the absorption of Omapatrilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Magnesium hydroxide.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Magnesium hydroxide.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Magnesium hydroxide.Approved, Illicit
OrbifloxacinMagnesium hydroxide can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
OrphenadrineMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Magnesium hydroxide.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Magnesium hydroxide.Investigational
OtiloniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Otilonium.Experimental, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Magnesium hydroxide.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Magnesium hydroxide.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Magnesium hydroxide.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Magnesium hydroxide.Approved
OXI-4503The serum concentration of OXI-4503 can be decreased when it is combined with Magnesium hydroxide.Investigational
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Magnesium hydroxide.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Magnesium hydroxide.Approved, Investigational, Nutraceutical
OxitropiumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Oxitropium.Investigational
Oxolinic acidMagnesium hydroxide can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Magnesium hydroxide.Approved
OxybutyninThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Magnesium hydroxide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Magnesium hydroxide.Experimental
OxyphencyclimineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Oxyphencyclimine.Approved
OxyphenoniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Oxyphenonium.Approved
OxytetracyclineMagnesium hydroxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Magnesium hydroxide.Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium hydroxide.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium hydroxide.Approved
ParaldehydeMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Magnesium hydroxide.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium hydroxide.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Magnesium hydroxide.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Magnesium hydroxide.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Paroxetine.Approved, Investigational
PazopanibMagnesium hydroxide can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinMagnesium hydroxide can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinMagnesium hydroxide can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenfluridolThe risk or severity of hypotension and neuromuscular blockade can be increased when Penfluridol is combined with Magnesium hydroxide.Experimental
PenicillamineMagnesium hydroxide can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenimepicyclineMagnesium hydroxide can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Magnesium hydroxide.Approved, Vet Approved
PenthienateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Penthienate.Experimental
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved
PerazineMagnesium hydroxide can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerflubutaneMagnesium hydroxide can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerindoprilMagnesium hydroxide can cause a decrease in the absorption of Perindopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerindoprilatMagnesium hydroxide can cause a decrease in the absorption of Perindoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Magnesium hydroxide.Approved
PerphenazineMagnesium hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Magnesium hydroxide.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Magnesium hydroxide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Magnesium hydroxide.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Magnesium hydroxide.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Magnesium hydroxide.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Magnesium hydroxide.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Magnesium hydroxide.Experimental
PhenglutarimideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Phenglutarimide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Magnesium hydroxide.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Magnesium hydroxide.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Magnesium hydroxide.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Magnesium hydroxide.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Magnesium hydroxide.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Magnesium hydroxide.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Magnesium hydroxide.Approved
PhentermineMagnesium hydroxide may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Magnesium hydroxide.Approved, Vet Approved
PimavanserinThe risk or severity of adverse effects can be increased when Pimavanserin is combined with Magnesium hydroxide.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Magnesium hydroxide.Approved
PinaveriumThe risk or severity of hypotension and neuromuscular blockade can be increased when Pinaverium is combined with Magnesium hydroxide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Magnesium hydroxide.Experimental
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Magnesium hydroxide.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium hydroxide.Approved
Pipemidic acidMagnesium hydroxide can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PipenzolateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Pipenzolate.Experimental
PiperidolateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Piperidolate.Experimental
PipotiazineMagnesium hydroxide can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PirenzepineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Pirenzepine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Magnesium hydroxide.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Magnesium hydroxide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pirlimycin is combined with Magnesium hydroxide.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Magnesium hydroxide.Approved
Piromidic acidMagnesium hydroxide can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Magnesium hydroxide.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Magnesium hydroxide.Withdrawn
PizotifenThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Plazomicin is combined with Magnesium hydroxide.Approved, Investigational
PoldineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Poldine.Experimental
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Polymyxin B Sulfate is combined with Magnesium hydroxide.Approved, Vet Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Magnesium hydroxide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Magnesium hydroxide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Potassium is combined with Magnesium hydroxide.Approved, Experimental
Potassium cationThe risk or severity of adverse effects can be increased when Potassium cation is combined with Magnesium hydroxide.Approved, Investigational
Potassium CitrateThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
PramipexoleMagnesium hydroxide may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Magnesium hydroxide.Approved, Illicit
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium hydroxide.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
PrednylideneThe bioavailability of Prednylidene can be decreased when combined with Magnesium hydroxide.Experimental
PregabalinThe therapeutic efficacy of Magnesium hydroxide can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of hypotension and neuromuscular blockade can be increased when Prenylamine is combined with Magnesium hydroxide.Withdrawn
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Magnesium hydroxide.Experimental
PrifiniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Prifinium.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Magnesium hydroxide.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Magnesium hydroxide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Magnesium hydroxide.Approved, Investigational
ProchlorperazineMagnesium hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ProcyclidineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Procyclidine.Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Magnesium hydroxide.Approved, Investigational
PromazineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Magnesium hydroxide.Experimental
PropanthelineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Propantheline.Approved
PropericiazineMagnesium hydroxide can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiomazineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Propiomazine.Approved
PropiopromazineMagnesium hydroxide can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PropiverineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Magnesium hydroxide.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Magnesium hydroxide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Magnesium hydroxide.Experimental
PrulifloxacinMagnesium hydroxide can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Prussian blueMagnesium hydroxide can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PseudoephedrineMagnesium hydroxide may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Magnesium hydroxide.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Puromycin is combined with Magnesium hydroxide.Experimental
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium hydroxide.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Magnesium hydroxide.Experimental
Pyrophosphoric acidThe serum concentration of Pyrophosphoric acid can be decreased when it is combined with Magnesium hydroxide.Approved, Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Magnesium hydroxide.Approved, Illicit
QuetiapineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Quetiapine.Approved
QuinaprilMagnesium hydroxide can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinaprilatMagnesium hydroxide can cause a decrease in the absorption of Quinaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Magnesium hydroxide.Approved
QuinidineMagnesium hydroxide may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineMagnesium hydroxide can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Magnesium hydroxide.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Magnesium hydroxide.Investigational
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium hydroxide.Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Magnesium hydroxide.Approved, Investigational
RamiprilMagnesium hydroxide can cause a decrease in the absorption of Ramipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RamiprilatMagnesium hydroxide can cause a decrease in the absorption of Ramiprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
RapacuroniumThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium hydroxide.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Magnesium hydroxide.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Magnesium hydroxide.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Magnesium hydroxide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Magnesium hydroxide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Magnesium hydroxide.Approved, Withdrawn
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Magnesium hydroxide.Approved
RescinnamineMagnesium hydroxide can cause a decrease in the absorption of Rescinnamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Magnesium hydroxide.Approved, Investigational
RevefenacinThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Revefenacin.Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Ribostamycin is combined with Magnesium hydroxide.Approved, Investigational
RifampicinMagnesium hydroxide can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Magnesium hydroxide.Approved, Investigational
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium hydroxide.Approved
RiociguatMagnesium hydroxide can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Magnesium hydroxide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Ritanserin.Investigational
RitobegronMagnesium hydroxide may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Rizatriptan.Approved
RociverineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Rociverine.Experimental
RocuroniumThe therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium hydroxide.Approved
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Magnesium hydroxide.Investigational
RolitetracyclineMagnesium hydroxide can cause a decrease in the absorption of Rolitetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Rolofylline is combined with Magnesium hydroxide.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Magnesium hydroxide.Vet Approved
RopiniroleMagnesium hydroxide may increase the sedative activities of Ropinirole.Approved, Investigational
RosoxacinMagnesium hydroxide can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinMagnesium hydroxide can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RotigotineMagnesium hydroxide may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when RP-5063 is combined with Magnesium hydroxide.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Magnesium hydroxide.Approved
RufloxacinMagnesium hydroxide can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SafinamideThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Magnesium hydroxide.Withdrawn
SarafloxacinMagnesium hydroxide can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved, Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Magnesium hydroxide.Investigational
ScopolamineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Magnesium hydroxide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension and neuromuscular blockade can be increased when Seletracetam is combined with Magnesium hydroxide.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Magnesium hydroxide.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Magnesium hydroxide.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when Sisomicin is combined with Magnesium hydroxide.Investigational
SitafloxacinMagnesium hydroxide can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium feredetateMagnesium hydroxide can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium glycerophosphateThe serum concentration of Sodium glycerophosphate can be decreased when it is combined with Magnesium hydroxide.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved
Sodium phosphate, monobasicThe serum concentration of Sodium phosphate, monobasic can be decreased when it is combined with Magnesium hydroxide.Approved
Sodium tartrateThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Sodium tartrate.Approved
Sodium tripolyphosphateThe serum concentration of Sodium tripolyphosphate can be decreased when it is combined with Magnesium hydroxide.Vet Approved
SolifenacinThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Solifenacin.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium hydroxide.Approved
SparfloxacinMagnesium hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SpiradolineThe risk or severity of adverse effects can be increased when Spiradoline is combined with Magnesium hydroxide.Investigational
SpiraprilMagnesium hydroxide can cause a decrease in the absorption of Spirapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Magnesium hydroxide.Approved
St. John's WortThe risk or severity of adverse effects can be increased when St. John's Wort is combined with Magnesium hydroxide.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Magnesium hydroxide.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Magnesium hydroxide.Approved, Vet Approved
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Magnesium hydroxide.Approved, Withdrawn
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Magnesium hydroxide.Experimental
SuccinylcholineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium hydroxide.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Magnesium hydroxide.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Magnesium hydroxide.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Magnesium hydroxide.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Sumatriptan.Approved, Investigational
SuvorexantMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Magnesium hydroxide.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Talopram is combined with Magnesium hydroxide.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Magnesium hydroxide.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Magnesium hydroxide.Approved
Tartaric acidThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tartaric acid.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Magnesium hydroxide.Approved, Investigational
Technetium Tc-99m ciprofloxacinMagnesium hydroxide can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Technetium Tc-99m polyphosphateThe serum concentration of Technetium Tc-99m polyphosphate can be decreased when it is combined with Magnesium hydroxide.Approved
Technetium Tc-99m pyrophosphateThe serum concentration of Technetium Tc-99m pyrophosphate can be decreased when it is combined with Magnesium hydroxide.Approved
TemafloxacinMagnesium hydroxide can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Magnesium hydroxide.Approved, Investigational
TemocaprilMagnesium hydroxide can cause a decrease in the absorption of Temocapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
TerodilineThe risk or severity of hypotension and neuromuscular blockade can be increased when Terodiline is combined with Magnesium hydroxide.Experimental
TetracyclineMagnesium hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TetraethylammoniumThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Tetraethylammonium.Experimental, Investigational
Tetraferric tricitrate decahydrateMagnesium hydroxide can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TetrahydropalmatineThe risk or severity of hypotension and neuromuscular blockade can be increased when Tetrahydropalmatine is combined with Magnesium hydroxide.Investigational
TetrandrineThe risk or severity of hypotension and neuromuscular blockade can be increased when Tetrandrine is combined with Magnesium hydroxide.Experimental
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Magnesium hydroxide.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Magnesium hydroxide.Investigational
ThalidomideMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Theobromine is combined with Magnesium hydroxide.Approved, Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Magnesium hydroxide.Approved, Vet Approved
ThiazinamMagnesium hydroxide can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineMagnesium hydroxide can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Magnesium hydroxide.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Magnesium hydroxide.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Magnesium hydroxide.Experimental
ThioproperazineMagnesium hydroxide can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThiopyrophosphateThe serum concentration of Thiopyrophosphate can be decreased when it is combined with Magnesium hydroxide.Experimental
ThioridazineMagnesium hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Magnesium hydroxide.Approved
ThonzylamineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Thonzylamine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Magnesium hydroxide.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Magnesium hydroxide.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Magnesium hydroxide.Approved, Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Ticrynafen is combined with Magnesium hydroxide.Withdrawn
Tiemonium iodideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tiemonium iodide.Experimental
TigecyclineMagnesium hydroxide can cause a decrease in the absorption of Tigecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Magnesium hydroxide.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Magnesium hydroxide.Experimental
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational, Vet Approved
TimepidiumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Timepidium.Experimental
TiotropiumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tiotropium.Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium hydroxide.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Magnesium hydroxide.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Tobramycin is combined with Magnesium hydroxide.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Magnesium hydroxide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Magnesium hydroxide.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Tolevamer.Approved, Investigational
Tolfenamic AcidThe risk or severity of hypotension and neuromuscular blockade can be increased when Tolfenamic Acid is combined with Magnesium hydroxide.Approved, Investigational
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Magnesium hydroxide.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Magnesium hydroxide.Approved, Investigational
TolterodineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tolterodine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Tolvaptan is combined with Magnesium hydroxide.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Magnesium hydroxide.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Magnesium hydroxide.Approved
TramadolThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tramadol.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Magnesium hydroxide.Investigational
TrandolaprilMagnesium hydroxide can cause a decrease in the absorption of Trandolapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TranilastThe risk or severity of hypotension and neuromuscular blockade can be increased when Tranilast is combined with Magnesium hydroxide.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Magnesium hydroxide.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Trazodone.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium hydroxide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Magnesium hydroxide.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Magnesium hydroxide.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Magnesium hydroxide.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Magnesium hydroxide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Magnesium hydroxide.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Magnesium hydroxide.Withdrawn
TridihexethylThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tridihexethyl.Withdrawn
TriethylenetetramineThe serum concentration of Magnesium hydroxide can be decreased when it is combined with Triethylenetetramine.Approved, Investigational
TrifluoperazineMagnesium hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Magnesium hydroxide.Experimental
TriflupromazineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Trihexyphenidyl.Approved
TrilostaneThe bioavailability of Trilostane can be decreased when combined with Magnesium hydroxide.Approved, Investigational, Vet Approved, Withdrawn
TrimebutineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension and neuromuscular blockade can be increased when Trimethadione is combined with Magnesium hydroxide.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Magnesium hydroxide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Magnesium hydroxide.Approved
TropatepineThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tropatepine.Experimental
TropicamideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Tropicamide.Approved, Investigational
TrospiumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Trospium.Approved
TrovafloxacinMagnesium hydroxide can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Tubocurarine.Approved
UlaritideThe risk or severity of adverse effects can be increased when Ularitide is combined with Magnesium hydroxide.Investigational
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Magnesium hydroxide.Approved
UmeclidiniumThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Umeclidinium.Approved
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Magnesium hydroxide.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Magnesium hydroxide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Magnesium hydroxide.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Magnesium hydroxide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium hydroxide.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium hydroxide.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Magnesium hydroxide.Experimental
VerapamilThe risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium hydroxide.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Magnesium hydroxide.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Magnesium hydroxide.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Magnesium hydroxide.Experimental
VinpocetineThe risk or severity of hypotension and neuromuscular blockade can be increased when Vinpocetine is combined with Magnesium hydroxide.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Magnesium hydroxide.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Magnesium hydroxide.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Magnesium hydroxide.Approved, Investigational
WIN 55212-2The risk or severity of hypotension and neuromuscular blockade can be increased when WIN 55212-2 is combined with Magnesium hydroxide.Experimental
XipamideThe risk or severity of adverse effects can be increased when Xipamide is combined with Magnesium hydroxide.Experimental
XP19986The risk or severity of adverse effects can be increased when XP19986 is combined with Magnesium hydroxide.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Magnesium hydroxide.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Magnesium hydroxide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of hypotension and neuromuscular blockade can be increased when Ziconotide is combined with Magnesium hydroxide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Magnesium hydroxide.Approved
ZofenoprilMagnesium hydroxide can cause a decrease in the absorption of Zofenopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Magnesium hydroxide.Vet Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium hydroxide.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Magnesium hydroxide is combined with Zolmitriptan.Approved, Investigational
ZolpidemMagnesium hydroxide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of hypotension and neuromuscular blockade can be increased when Zonisamide is combined with Magnesium hydroxide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Magnesium hydroxide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Magnesium hydroxide.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Magnesium hydroxide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Wikipedia [Link]
  2. Drugs.com [Link]
  3. Glow [Link]
  4. Medicines [Link]
  5. Drugs.com [Link]
External Links
KEGG Compound
C07876
PubChem Compound
73981
PubChem Substance
310265028
ChemSpider
14107
ChEBI
6637
ChEMBL
CHEMBL1200718
Wikipedia
Magnesium_hydroxide
ATC Codes
A02AA04 — Magnesium hydroxideG04BX01 — Magnesium hydroxide
AHFS Codes
  • 56:04.00 — Antacids and Adsorbents
  • 84:24.12 — Basic Ointments and Protectants
  • 56:12.00 — Cathartics and Laxatives
  • 84:24.00 — Emollients Demulcents and Protectants

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers3
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentChronic Kidney Disease (CKD) / Hypomagnesaemia1
2CompletedNot AvailableAcid Reflux Disease / Gastro-esophageal Reflux Disease (GERD) / Heartburn / Regurgitation1
3TerminatedTreatmentRadiation-induced Oesophagitis1
4CompletedTreatmentEmergency / Indigestion / Pain1
Not AvailableCompletedPreventionPost Procedural Constipation1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, chewableOral
OintmentTopical.25 %
OintmentTopical0.25 %
SolutionOral
GelOral
TabletOral
SuspensionOral1200 mg/15mL
SuspensionOral80 mg/mL
LiquidOral1200 mg/15mL
LiquidOral
SuspensionOral
TabletOral385 mg
EmulsionOral
ConcentrateOral2400 mg/10mL
LiquidOral400 mg/5mL
LiquidOral400 mg
SuspensionOral2400 mg/30mL
SuspensionOral2400 mg/10mL
SuspensionOral400 mg/5mL
SuspensionOral7.75 %
LiquidOral8 g
TabletOral300 mg
SuspensionOral400 mg
SuspensionOral80 mg
SuspensionOral440 mg
Tablet, chewableOral400 mg/1
LiquidOral80 mg
Tablet, chewableOral311 mg/1
LiquidOral2400 mg/15mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6489346No1996-07-162016-07-16Us
US6699885No1996-07-162016-07-16Us
US6645988No1996-07-162016-07-16Us
US7399772No1996-07-162016-07-16Us
US6814978Yes2002-02-262022-02-26Us
US5989588Yes1998-03-302018-03-30Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.57ChemAxon
pKa (Strongest Acidic)3.09ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkaline earth metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkaline earth metal oxoanionic compounds
Sub Class
Alkaline earth metal hydroxides
Direct Parent
Alkaline earth metal hydroxides
Alternative Parents
Inorganic salts / Inorganic oxides / Inorganic hydrides
Substituents
Alkaline earth metal hydroxide / Inorganic hydride / Inorganic oxide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
magnesium hydroxide (CHEBI:6637)

Drug created on September 16, 2015 16:26 / Updated on August 15, 2018 09:56